Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease
-
Published:2022-10
Issue:
Volume:547
Page:215775
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Mehlich DawidORCID,
Marusiak Anna A.ORCID
Subject
Cancer Research,Oncology
Reference122 articles.
1. Triple-negative breast cancer;Foulkes;N. Engl. J. Med.,2010
2. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease;Bianchini;Nat. Rev. Clin. Oncol.,2016
3. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N. Engl. J. Med.,2018
4. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer;Miles;Ann. Oncol.,2021
5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial;Cortes;Lancet,2020
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献